Register entry
BAUSCH HEALTH AMERICAS INC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 44
- Countries
- 0
Exclusivity
Patents and exclusivities
44| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10512640 | JUBLIAefinaconazole | use | Jan 2028 |
| 10828369 | JUBLIAefinaconazole | product | Jan 2028 |
| 11213519 | JUBLIAefinaconazole | use | Jan 2028 |
| 11872218 | JUBLIAefinaconazole | use | Jan 2028 |
| 9566272 | JUBLIAefinaconazole | use | Jan 2028 |
| 9877955 | JUBLIAefinaconazole | use | Jan 2028 |
| 10137142 | ONEXTONbenzoyl peroxide; clindamycin phosphate | product | Jun 2029 |
| 10220049 | ACANYA, ONEXTONbenzoyl peroxide; clindamycin phosphate | product | Jun 2029 |
| 10624918 | ACANYAbenzoyl peroxide; clindamycin phosphate | use | Jun 2029 |
| 8663699 | ACANYAbenzoyl peroxide; clindamycin phosphate | use | Jun 2029 |
| 8895070 | ACANYAbenzoyl peroxide; clindamycin phosphate | use | Jun 2029 |
| 9078870 | ACANYAbenzoyl peroxide; clindamycin phosphate | product | Jun 2029 |
| 9504704 | ONEXTONbenzoyl peroxide; clindamycin phosphate | product | Jun 2029 |
| 9561208 | ONEXTONbenzoyl peroxide; clindamycin phosphate | product | Jun 2029 |
| 8288434 | ACANYA, ONEXTONbenzoyl peroxide; clindamycin phosphate | product | Aug 2029 |
| 10105444 | JUBLIAefinaconazole | product | Jul 2030 |
| 8039494 | JUBLIAefinaconazole | use | Jul 2030 |
| 9861698 | JUBLIAefinaconazole | product | Jul 2030 |
| 8486978 | JUBLIAefinaconazole | product | Oct 2030 |
| 9302009 | JUBLIAefinaconazole | product | Oct 2030 |
| 10478502 | BRYHALI, DUOBRIIhalobetasol propionate; halobetasol propionate; tazarotene | product | Nov 2031 |
| 11839656 | BRYHALI, DUOBRIIhalobetasol propionate; halobetasol propionate; tazarotene | use | Nov 2031 |
| 11957753 | BRYHALI, DUOBRIIhalobetasol propionate; halobetasol propionate; tazarotene | product | Nov 2031 |
| 11986527 | BRYHALI, DUOBRIIhalobetasol propionate; halobetasol propionate; tazarotene | use | Nov 2031 |
| 12076403 | BRYHALI, DUOBRIIhalobetasol propionate; halobetasol propionate; tazarotene | product | Nov 2031 |
| 8809307 | BRYHALI, DUOBRIIhalobetasol propionate; halobetasol propionate; tazarotene | product | Nov 2031 |
| 10342875 | JUBLIAefinaconazole | product | Oct 2034 |
| 10828293 | JUBLIAefinaconazole | use | Oct 2034 |
| 10864274 | JUBLIAefinaconazole | use | Oct 2034 |
| 11654139 | JUBLIAefinaconazole | use | Oct 2034 |
| 9662394 | JUBLIAefinaconazole | product | Oct 2034 |
| 10478601 | JUBLIAefinaconazole | product | Apr 2035 |
| 10251895 | DUOBRIIhalobetasol propionate; tazarotene | product | Jun 2036 |
| 10426787 | DUOBRIIhalobetasol propionate; tazarotene | use | Jun 2036 |
| 11648256 | DUOBRIIhalobetasol propionate; tazarotene | product | Jun 2036 |
| 11679115 | DUOBRIIhalobetasol propionate; tazarotene | product | Jun 2036 |
Enquiry
Common questions
- Is BAUSCH HEALTH AMERICAS INC FDA approved?
- BAUSCH HEALTH AMERICAS INC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.